We pooled data from patients enrolled in the Ibaraki Cardiovascular Assessment Study (ICAS) registry, which is a multicenter registry involving 12 hospitals in Ibaraki Prefecture, Japan. All traceable personal identifiers were removed from the data sets before analysis to protect patient confidentiality. 
B
ecause early randomized trials showed that dual antiplatelet therapy is superior to the combination of aspirin and warfarin in the prevention of stent thrombosis, [1] [2] [3] current guidelines on percutaneous coronary intervention (PCI) have recommended combined aspirin and clopidogrel therapy after stent deployment. Oral anticoagulation with warfarin improves outcome and decreases the incidence of cerebral and peripheral embolism in patients who are at high risk of thromboembolic events. 4 An increasing number of patients requiring long-term oral anticoagulation with warfarin have undergone PCI. Several studies showed that triple antithrombotic therapy (combination of aspirin, clopidogrel, and warfarin) increases the risk of bleeding events in patients undergoing PCI. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Recently, analysis of percent time in the therapeutic range (TTR) has been used to assess the appropriateness of the international normalized ratio of prothrombin time (PT-INR). 15 However, whether good control of TTR was associated with reduced occurrence of bleeding complications in the patients with triple antithrombotic therapy remains unclear. Therefore, the aim of this study was to clarify the relation between the control of TTR and the occurrence of major bleeding complications (MBCs) in the clinical setting of a large-scale multicenter registry.
Study Population
Written informed consent was obtained from all patients, and data collection for this study was approved by each institution's review board. This was a retrospective cohort study that included 3037 Japanese patients who underwent PCI in the ICAS registry between April 2007 and August 2010. Of these 3037 patients, 155 were excluded because of no information on follow-up outcome. Another 151 patients experienced a prior PCI, 48 patients underwent balloon angioplasty only, and 35 patients did not received dual antiplatelet therapy. After excluding these patients, the remaining 2648 patients comprised the study group.
All included patients were discharged on clopidogrel 75 mg and aspirin 100 to 200 mg daily. The standard of care at discharge was to prescribe clopidogrel for ≥1 year to all patients treated with drugeluting stents (DESs) and for ≥3 months to patients treated with baremetal stents. All patients were advised to maintain aspirin lifelong. All patients were followed up at 2 to 4 weeks after the PCI and then every 1 month at the outpatient clinic for >1 year. Follow-up angiography was also performed at 6 to 12 months after PCI.
Data were collected on cardiac risk factors, such as hypertension, hyperlipidemia, diabetes mellitus, and smoking, and on laboratory test findings, left ventricular ejection fraction, type of stent implanted, culprit artery, medications, and clinical outcomes during a median followup period of 25 months (interquartile range [IQR], 15-35 months). Hypertension, hypercholesterolemia, and diabetes mellitus were scored on the basis of previous diagnosis or initiation of therapy for the condition. Congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke (CHADS2) score was retrospectively calculated.
Anticoagulation
The enrolled patients were classified into 2 groups according to treatment with (n=182) or without warfarin (n=2466) at the discharge. Reasons for taking warfarin included atrial fibrillation (AF) in 143 patients, deep vein thrombus in 16, mechanical valve in 14, and intraventricular thrombus in the remaining 9 ( Figure 1 ). Among 182 patients, 17 patients did not take warfarin at the PCI procedure and start to take that after PCI because of intraventricular thrombus (n=9), AF (n=5), and deep vein thrombus (n=3). In patients taking warfarin, the target PT-INR was set between 1.6 and 2.5 and was closely monitored after discharge. The reason why we set the target PT-INR level of 1.6 to 2.5 was that major hemorrhagic events occur often in the Japanese patients with AF whose PT-INR level was >2.6 and the prevalence of stroke occurrence did not increase in the Japanese patients with PT-INR level of 1.6 to 2.0 compared with those >2.0. 16 Initially, measurements of PT-INR were performed weekly and if the PT-INR had achieved the target value after 2 consecutive visits, then measurements were taken monthly. Pharmacists of all hospitals performed an interview to patients about the adherence to the prescribed regimens at any of the follow-up visits.
The TTR of the PT-INR is the proportion of the estimated period in which the INR is within the target range to the total follow-up period. TTR was calculated using the method described by Rosendaal et al, 17 which assumes that changes between consecutive INR measurements are linear over time. Using specially programmed software (Eisai, Tokyo, Japan), we input the successive PT-INR values of each patient and calculated the TTR. This software automatically draws lines successively between any 2 consecutive PT-INR values during the observation period and calculates the percentage of the total time within the target range during the entire period.
Study End Points
Clinical primary end point was defined as the occurrence of MBCs, and secondary end points were all-cause death and major adverse cardiac and cerebrovascular event, including cardiac death, myocardial infarction, stent thrombosis, stroke, and target vessel revascularization. MBCs were defined as cerebral hemorrhage or gastrointestinal bleeding. Gastrointestinal bleeding was identified by
WHAT IS KNOWN
• An increasing number of patients requiring longterm oral anticoagulation with warfarin have undergone percutaneous coronary intervention with stent placement.
• Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention.
• Recently, analysis of percent time in the therapeutic range has been used to assess the appropriateness of the international normalized ratio of prothrombin time.
WHAT THE STUDY ADDS
• Triple antithrombotic therapy predisposes patients to an increased risk of major bleeding complications regardless of the time in the therapeutic range. hematemesis or melena and a reduction in hemoglobin level of ≥2 g/ dL. Cerebral hemorrhage was adjudicated by a neurologist and was confirmed by computed tomographic scanning. Myocardial infarction was defined as a rise in the MB fraction of the creatine kinase of above the 99th percentile of the upper reference limit together with symptoms of ischemia, ECG changes indicative of new ischemia (new ST-T changes or new left bundle-branch block), and development of pathological Q waves on the ECG. 18 Stent thrombosis was defined according to Academic Research Consortium criteria, and only definite stent thrombosis was counted. 19 Stroke was defined as an ischemic cerebral infarction caused by an embolic or thrombotic occlusion of a major intracranial artery. Acute groin site hemorrhages was not included in study end points because the main purpose of this study was to assess the efficacy and safety of long-term triple antithrombotic therapy. 
Statistical Analysis

Results
Demographic and Clinical Characteristics of the Patients With and Without Warfarin
Among the 2648 patients, 182 (7%) received warfarin. There was no significant difference in sex, body mass index, laboratory test results, and DESs between the 2 groups. However, the Values are reported as the mean±SD, medians (interquartile range), or n (%). ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke; DAPT, dual antiplatelet therapy; LAD, left anterior descending artery; LCx, left circumflex artery; LMT, left main trunk; PCI, percutaneous coronary intervention; RCA, right coronary artery; and WF, warfarin.
patients with warfarin were older (P<0.05) and had a higher prevalence of prior cerebral infarction (P<0.05), β-blocker use (P<0.01), and PCI to graft (P<0.05) than those without. The prevalence of diabetes mellitus (P<0.01) and elective PCI (P<0.05) was lower, left ventricular ejection fraction was lower (P<0.001), and CHADS2 score was higher (P<0.01) in the patients with warfarin than in those without (Table 1) .
Among the 2648 patients, 1906 (72%) patients continued dual antiplatelet therapy throughout the median follow-up period of 25 months (IQR, 15-35 months) . The prevalence of continuing dual antiplatelet therapy throughout the follow-up period was lower in the patients with warfarin than in those without warfarin (66% versus 78%; P<0.001).
Occurrence of MBCs in the Patients With and Without Warfarin
After a median follow-up of 25 months (IQR, 15-35 months) and 5517 person-years (IQR, 3413-7198 person-years), 48 (2%; 0.9 per 100 person-years) patients had experienced an episode of MBCs. Gastrointestinal bleeding occurred in 38 patients and cerebral hemorrhage in the remaining 10. The prevalence of MBCs was higher in the patients with warfarin than in those without (P<0.001; Table 2 ). Kaplan-Meier curves showed that warfarin administration was associated with increased risk for the occurrence of MBCs (P<0.01 by log-rank test; Figure 2 (Table 3) .
When the details of MBCs were analyzed, the prevalence of gastrointestinal bleeding was higher in the patients with triple antithrombotic therapy than in those with dual antiplatelet therapy (P<0.01; Table 2 ). Although the incidence of cerebral hemorrhage did not differ between the 2 groups (P=0.06; Table 2 ), the patients with triple antithrombotic therapy had an increased risk of fatal cerebral hemorrhage compared with those with dual antiplatelet therapy (P<0.001; Table 2 ).
The median TTR was 76% (IQR, 49%-87%) in our study population. Among the 9 patients who took warfarin and experienced an episode of MBCs, the median TTR throughout this study period was 83% (IQR, 50%-90%), and it did not differ significantly compared with the patients without the occurrence of MBCs (75% [IQR, 58%-87%]; P=0.7, Figure 3A) . However, the mean PT-INR at the time of occurrence of MBCs was 3.3±2.1: <1.6 in 1 patient, 1.6 to 2.5 in 2 patients, and >2.5 in the remaining 6 patients ( Figure 3B ).
Occurrence of Secondary End Points in the Patients With and Without Warfarin
Among the 2648 patients, a major adverse cardiac and cerebrovascular event occurred in 484 (18%; 8.77 per 100 personyears) patients and all-cause death occurred in 206 (8%; 3.73 per 100 person-years) patients ( Table 2 ). The prevalence of cardiac death, myocardial infarction, stent thrombosis, target vessel revascularization, stroke, overall major adverse cardiac event (MACE), and overall major adverse cardiac and cerebrovascular event did not differ significantly between the patients with and without warfarin ( Table 2 ). The patients with triple antithrombotic therapy have higher prevalence of all-cause death than those with dual antiplatelet therapy (5.90 per 100 person-years versus 3.52 per 100 person-years; P<0.05; Table 2 ).
Multivariable Cox proportional regression analyses showed that warfarin administration was not an independent predictor for the occurrences of all-cause death (HR, 1 Values are reported as the n (per 100 person-years). MAC(C)E indicates major adverse cardiac (and cerebrovascular) event.
(P<0.001), elective PCI (P<0.001), DES (P<0.01), use of a statin (P<0.001), angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (P<0.001), β-blocker (P<0.001), and proton pump inhibitor (P<0.05) were significantly associated with the occurrence of all-cause death (Table 4) . CHADS2 (P<0.001) score was an independent predictor of increased occurrence of stroke; and calcium channel blocker administration (P<0.05) and DES (P<0.01) had predictive value for the reduced occurrence of stroke (Table 4) . Diabetes mellitus (P<0.01) had an increased risk for the occurrence of overall MACE; hemoglobin level (P<0.05), statin administration (P<0.001), elective PCI (P<0.001), and DES (P<0.001) were independent predictors for the lower occurrence of overall MACE (Table 4) . 
Subgroup Analysis in the Patients
Discussion
The major important findings of the present study are as follows: (1) ≈7% of the patients who underwent PCI took warfarin; (2) triple antithrombotic therapy was an independent predictor for the occurrence of MBCs; (3) the TTR level did not differ between the patients with and without the occurrence of MBCs (however, the mean PT-INR at the occurrence of MBCs was 3.3±2.1); and (4) triple antithrombotic therapy was not an independent predictor for the occurrence of allcause death, stroke, and overall MACE.
Necessity of Warfarin Administration in Patients at High Risk of Thromboembolic Events
Several studies reported that dual antiplatelet therapy had an increased risk for the occurrence of stroke compared with triple antithrombotic therapy in patients with AF who underwent PCI. 5, 20 Our study showed that there was no significant difference in the occurrence of stroke between the patients with and without warfarin. We have to acknowledge that warfarin administration is needed in patients at high risk of thromboembolic events. However, triple antithrombotic therapy actually predisposes patients to an increased risk of MBCs.
Adequate PT-INR Range in the Patient With Triple Antithrombotic Therapy
Our study showed that the PT-INR value at the time of a MBC was >2.6 in 6 (67%) of the 9 patients who took warfarin and experienced an episode of MBCs. A recent study showed that a PT-INR of >2.6 was the only independent predictor of bleeding. 21 As the guidelines recommended, when warfarin is given in combination with clopidogrel and low-dose aspirin, the dose intensity must be carefully regulated, with a target INR of 2.0 to 2.5. 22, 23 Although we try to set the INR between 1.6 and 2.5 in this study, the recommendation in the guideline suggests an INR between 2.0 and 2.5 in Western countries. Therefore, the target PT-INR range of 1.6 to 2.5 was not accepted for stroke prophylaxis in AF in Western countries. A recent study reported that major hemorrhagic events occur often in especially the elderly (>70 years) Japanese patients with AF whose PT-INR level was >2.6, and the prevalence of stroke occurrence did not increase in the patients with PT-INR level of 1.6 to 2.0 compared with those with PT-INR level of >2.0. 16 Moreover, guideline of Japanese circulation society recommends that the target PT-INR level was set between 1.6 and 2.6 in the elderly patients with AF to avoid bleeding complication. Among 2648 patients in this study, 1411 (53%) was elderly patients. Therefore, most of the physicians participating ICAS registry tended to control the PT-INR level ≈2.0 (between 1.6 and 2.5).
Clinical Implications
The present study showed that triple antithrombotic therapy was significantly associated with an increased risk for the occurrence of MBCs, and the PT-INR level was >2.5 in most of patients who experienced a MBC with triple antithrombotic therapy. Because the mean TTR level did not differ between the patients with and without the occurrence of MBCs, triple therapy should only be prescribed for the shortest necessary time with frequent INR measurement to maintain a target INR of 2 to 2.5.
Because the use of DESs necessitates prolonged dual antiplatelet therapy to prevent stent thrombosis, 24 in patients with a compelling indication for long-term anticoagulation, baremetal stent implantation or stand-alone balloon angioplasty or coronary artery bypass grafting should be preferred compared with DES to restrict the duration of triple antithrombotic therapy to 1 month. 23, 25 However, the prevalence of bare-metal stent use did not differ between the patients with and without MBCs in our study. Dual antiplatelet therapy was continued ≥3 months in all patients regardless of the type of stent used in the present study, and that could affect the result. The prevalence of continuing dual antiplatelet therapy throughout the follow-up period was relatively high in our study according to the physician's decision. It may affect the increasing occurrence of MBCs. We should use dual antiplatelet therapy as short as possible following the recommendations. 22, 23, 25 Recent evidence from the WOEST (What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing) trial showed that double therapy (combination of clopidogrel and warfarin) had a lower prevalence of bleeding complications and did not differ in the occurrence of stent thrombosis compared with triple therapy. 26 Therefore, double therapy without aspirin should ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac event; and PCI, percutaneous coronary intervention.
be considered as an effective therapeutic option in patients requiring long-term oral anticoagulation with warfarin and who are undergoing PCI with stent placement.
Study Limitations
Potential limitations of our study should be noted. First, the small number of patients treated with triple antithrombotic therapy and the low incidence of primary end point should be taken into account when considering the results. Especially the number of the patients who experienced MBCs with warfarin was so small (n=9) that it was hard to look for an association with TTR. The ability to draw conclusions is limited largely by the small number of events and patients who received warfarin. This is likely to be because of the retrospective nature of the analysis and to the fact that most registries until recently have been focused on ischemic events rather than bleeding, leading to likely underreporting. Second, our study was of a retrospective nonrandomized design. Third, all subjects included in this study were Japanese and the target PT-INR level applied to Japanese (between 1.6 and 2.5) was different from those to the patients of Western country (between 2.0 and 2.5). Therefore, further prospective studies with a larger sample size, long-term follow-up, and the participation of many hospitals and many countries may be needed to resolve these limitations and to ensure and enhance our results.
Conclusions
This study showed that triple antithrombotic therapy predisposed patients to an increased risk of MBCs regardless of the TTR.
